Brokerages Set Cencora, Inc. (NYSE:COR) Price Target at $399.00

Shares of Cencora, Inc. (NYSE:COR) have received an average rating of “Moderate Buy” from the fourteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $403.1667.

Several research firms have issued reports on COR. Barclays lifted their target price on Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a research note on Friday, February 13th. Wall Street Zen lowered shares of Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. Evercore restated an “outperform” rating on shares of Cencora in a report on Tuesday. JPMorgan Chase & Co. lifted their price objective on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Finally, Weiss Ratings upgraded shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research note on Thursday, February 5th.

Cencora Stock Down 3.2%

Cencora stock opened at $334.69 on Friday. The business has a fifty day moving average of $355.45 and a two-hundred day moving average of $339.50. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62. The firm has a market cap of $65.11 billion, a P/E ratio of 40.23, a P/E/G ratio of 1.61 and a beta of 0.68. Cencora has a twelve month low of $260.23 and a twelve month high of $377.54.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. The business had revenue of $85.93 billion for the quarter, compared to the consensus estimate of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The business’s revenue was up 5.5% compared to the same quarter last year. During the same period last year, the business posted $3.73 EPS. On average, analysts forecast that Cencora will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were issued a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, February 13th. Cencora’s payout ratio is currently 28.85%.

Insider Transactions at Cencora

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the transaction, the executive vice president directly owned 23,891 shares in the company, valued at $8,173,111.10. The trade was a 12.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Silvana Battaglia sold 1,677 shares of the company’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the transaction, the executive vice president directly owned 18,796 shares in the company, valued at $6,484,620. This represents a 8.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 15,220 shares of company stock valued at $5,282,867. Corporate insiders own 0.38% of the company’s stock.

Institutional Investors Weigh In On Cencora

Several institutional investors have recently added to or reduced their stakes in COR. Kemnay Advisory Services Inc. acquired a new position in shares of Cencora during the fourth quarter valued at about $25,000. Oakworth Capital Inc. acquired a new stake in Cencora in the 4th quarter worth approximately $26,000. Elyxium Wealth LLC purchased a new stake in Cencora during the 4th quarter worth approximately $27,000. Archer Investment Corp grew its position in Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after purchasing an additional 47 shares during the last quarter. Finally, Motiv8 Investments LLC acquired a new position in Cencora during the 4th quarter valued at approximately $29,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.